Engineered Osteoclasts for the Treatment and Prevention of Heterotopic Ossification

Abstract

Heterotopic ossification (HO) is the abnormal formation of bone in soft tissues and is a frequent complication in patients who have suffered traumatic brain and spinal cord injuries. Currently there are few effective treatments for this condition. This research seeks to develop engineered osteoclasts as a local cell therapy for the prevention and/or regression of HO. The goals of this research are to develop proof-of-principle data in excised human HO specimens and in an animal model using existing murine engineered osteoclasts and to develop an off-the-shelf human cell source for clinical translation of this technology. To date we have performed studies to optimize the delivery and formation of engineered osteoclasts in vivo. In a pilot study, delivery and activation of engineered osteoclasts at the site of HO formation resulted in a reduction of HO formation. We have also validated a protocol for the production of human CD34+ cells from fibroblasts that we will combine with our CID technology for the production of human engineered osteoclasts.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2015
Accession Number
AD1001590

Entities

People

  • Bruce Sangeorzan
  • Cecilia Giachelli
  • Steven Bain
  • Susan Lund

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Cells
  • Embryos
  • Fibroblasts
  • Heterotopic Ossification
  • Osteogenesis
  • Pilot Studies
  • Production
  • Soft Tissues
  • Spinal Cord
  • Spinal Injuries
  • Stem Cells
  • Stromal Cells
  • Tissues
  • Translations

Fields of Study

  • Medicine

Readers

  • Aerial Delivery - Logistics and Supply Chain Management.
  • Neurotrauma and Rehabilitation Medicine.
  • Oncology (Cancer Research).